


0300  
Box Sequence  
PATENT

Attorney Docket No: 01017/36917A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Medlock et al.

Serial No: 09/810,927

Filed: March 16, 2001

Title: IL-17 Receptor Like Molecules  
and Uses Thereof

Group Art Unit: 1645

Examiner: TBA

) I hereby certify that this paper is being  
) deposited with the United States Postal  
) Service as first class mail, postage  
) prepaid, in an envelope addressed to the  
) Commissioner for Patents, Washington,  
) D.C., 20231.

) February 15, 2002

) Thomas A. Cawley, Jr.

) Thomas A. Cawley, Jr., Ph.D.

) Registration No. 40,944

Attorney for Applicants

**RESPONSE TO "NOTICE TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES"**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures" dated February 5, 2002 (copy enclosed herewith). Accompanied herewith is a replacement computer-readable copy of the Sequence Listing as filed in the Preliminary Amendment dated November 9, 2001, as well as a "Statement pursuant to 37 C.F.R. §§1.825(a) and (b)."

**II. REMARKS**

In response to the communication referred to above, the applicants have replaced the damaged diskette containing the Sequence Listing of record with a replacement diskette. For the convenience of the examiner, a additional paper copy of the Sequence

Listing is also submitted herewith (which is an exact duplicate of the paper copy of the Sequence Listing provided to the Patent Office on November 9, 2001). Accompanying the paper and computer-readable copies of the Sequence Listing is a "Statement Pursuant to 37 C.F.R. §§1.825(a) and (b).

In view of the foregoing, the applicants submit that no new matter has been added via the submission of the replacement diskette for the Sequence Listing of record.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

By:



---

Thomas A. Cawley, Jr., Ph.D.  
Registration No. 40,994  
Attorney for Applicants

February 15, 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/810,927	03/16/2001	Eugene Medlock	01017/36917A

CONFIRMATION NO. 7150

04743  
MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN  
6300 SEARS TOWER  
233 SOUTH WACKER DRIVE  
CHICAGO, IL 60606-6402

## FORMALITIES LETTER



\*OC0000000074 19647\*

Docketed: 4-5-02

Date Mailed: 02/05/2002



### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE